<DOC>
	<DOC>NCT00201812</DOC>
	<brief_summary>To determine the safety and efficacy of the combination of Etanercept and Docetaxel in patients with advanced solid tumors for which there is no standard treatment.</brief_summary>
	<brief_title>Phase I &amp; Biological Study of Etanercept &amp; Weekly Docetaxel in Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Must have pathologically or cytologically confirmed advanced solid malignancy for which there is no standard treatment exists. Solid malignancy that has persisted or recurred following prior therapy or advanced solid malignancy for which docetaxel is considered an acceptable first line treatment option: NonSmall Cell Lung Breast Head and Neck Esophageal Stomach Ovarian carcinomas Eastern Cooperative Oncology Group (ECOG) Performance Status of 02 Life expectancy of at least 12 weeks. Must have adequate organ function Peripheral Neuropathy must be less than Grade 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Advanced Solid Tumors</keyword>
</DOC>